Role of Immunoglobulin A in COVID-19 and Influenza Infections

Overview

Journal Vaccines (Basel)

Date 2023 Nov 25

PMID 38005979

Authors

Rohit Tyagi

Srijani Basu

Atika Dhar

Suman Gupta

Sneh Lata Gupta

Rishi K Jaiswal

Affiliations

Soon will be listed here.

Abstract

Immunoglobulin A (IgA) is critical in the immune response against respiratory infections like COVID-19 and influenza [...].

Citing Articles

A Possible Protective Effect of IgA Against Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) in Bronchoalveolar Lavage in COVID-19 Patients Admitted to Intensive Care Unit.

Di Stefano M, Mirabella L, Cotoia A, Faleo G, Rauseo M, Rizzo A Viruses. 2025; 16(12.

PMID: 39772161 PMC: 11680283. DOI: 10.3390/v16121851.

COVID-19 on Oral Health: A New Bilateral Connection for the Pandemic.

Bellocchio L, Dipalma G, Inchingolo A, Inchingolo A, Ferrante L, Del Vecchio G Biomedicines. 2024; 12(1).

PMID: 38255167 PMC: 10813615. DOI: 10.3390/biomedicines12010060.

References

Pabst R . Mucosal vaccination by the intranasal route. Nose-associated lymphoid tissue (NALT)-Structure, function and species differences. Vaccine. 2015; 33(36):4406-13. DOI: 10.1016/j.vaccine.2015.07.022. View

King J, McLean H, Meece J, Levine M, Spencer S, Flannery B . Vaccine failure and serologic response to live attenuated and inactivated influenza vaccines in children during the 2013-2014 season. Vaccine. 2018; 36(9):1214-1219. DOI: 10.1016/j.vaccine.2018.01.016. View

Quinti I, Piano Mortari E, Salinas A, Milito C, Carsetti R . IgA Antibodies and IgA Deficiency in SARS-CoV-2 Infection. Front Cell Infect Microbiol. 2021; 11:655896. PMC: 8057809. DOI: 10.3389/fcimb.2021.655896. View

Park H, Matsuoka Y, Luongo C, Yang L, Santos C, Liu X . Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. NPJ Vaccines. 2022; 7(1):72. PMC: 9240059. DOI: 10.1038/s41541-022-00493-x. View

Achdout H, Vitner E, Politi B, Melamed S, Yahalom-Ronen Y, Tamir H . Increased lethality in influenza and SARS-CoV-2 coinfection is prevented by influenza immunity but not SARS-CoV-2 immunity. Nat Commun. 2021; 12(1):5819. PMC: 8492774. DOI: 10.1038/s41467-021-26113-1. View

Abreu R, Clutter E, Attari S, Sautto G, Ross T . IgA Responses Following Recurrent Influenza Virus Vaccination. Front Immunol. 2020; 11:902. PMC: 7249748. DOI: 10.3389/fimmu.2020.00902. View

Liew F, Talwar S, Cross A, Willett B, Scott S, Logan N . SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine. 2022; 87:104402. PMC: 9762734. DOI: 10.1016/j.ebiom.2022.104402. View

Krammer F, Smith G, Fouchier R, Peiris M, Kedzierska K, Doherty P . Influenza. Nat Rev Dis Primers. 2018; 4(1):3. PMC: 7097467. DOI: 10.1038/s41572-018-0002-y. View

Waltz E . China and India approve nasal COVID vaccines - are they a game changer?. Nature. 2022; 609(7927):450. DOI: 10.1038/d41586-022-02851-0. View

10.

Tioni M, Jordan R, Pena A, Garg A, Wu D, Phan S . Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. NPJ Vaccines. 2022; 7(1):85. PMC: 9334537. DOI: 10.1038/s41541-022-00509-6. View

11.

Huang J, Ding Y, Yao J, Zhang M, Zhang Y, Xie Z . Nasal Nanovaccines for SARS-CoV-2 to Address COVID-19. Vaccines (Basel). 2022; 10(3). PMC: 8952855. DOI: 10.3390/vaccines10030405. View

12.

. Influenza vaccine for 2019-2020. Med Lett Drugs Ther. 2019; 61(1583):161-166. View

13.

Zhu F, Zhuang C, Chu K, Zhang L, Zhao H, Huang S . Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Respir Med. 2022; 10(8):749-760. PMC: 9135375. DOI: 10.1016/S2213-2600(22)00131-X. View

14.

Chen J, Wang P, Yuan L, Zhang L, Zhang L, Zhao H . A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Sci Bull (Beijing). 2022; 67(13):1372-1387. PMC: 9134758. DOI: 10.1016/j.scib.2022.05.018. View

15.

Gupta S, Jaiswal R . Relevant of neutralizing antibody during SARS-CoV-2 infection and their therapeutic usage. Mol Biol Rep. 2022; 49(10):10137-10140. PMC: 9123622. DOI: 10.1007/s11033-022-07493-z. View

16.

Zimmerman R, Nowalk M, Chung J, Jackson M, Jackson L, Petrie J . 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. Clin Infect Dis. 2016; 63(12):1564-1573. PMC: 5146719. DOI: 10.1093/cid/ciw635. View

17.

Stamatatos L, Czartoski J, Wan Y, Homad L, Rubin V, Glantz H . mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science. 2021; . PMC: 8139425. DOI: 10.1126/science.abg9175. View

18.

Gupta S, Jaiswal R . An Assessment of the Bivalent Vaccine as a Second Booster for COVID-19. Vaccines (Basel). 2023; 11(1). PMC: 9863048. DOI: 10.3390/vaccines11010079. View

19.

Gupta S, Tyagi R, Dhar A, Oswal N, Khandelwal A, Jaiswal R . Children's SARS-CoV-2 Infection and Their Vaccination. Vaccines (Basel). 2023; 11(2). PMC: 9962844. DOI: 10.3390/vaccines11020418. View

20.

Le Nouen C, Nelson C, Liu X, Park H, Matsuoka Y, Luongo C . Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell. 2022; 185(25):4811-4825.e17. PMC: 9684001. DOI: 10.1016/j.cell.2022.11.006. View